Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling

Journal of Endocrinological Investigation

Volumn 35, Issue 7, 2012, Pages 655-660

  Cetani, F ^a   Saponaro, F ^a   Banti, C ^a   Cianferotti, L ^a   Vignali, E ^a   Chiavistelli, S ^a   Viccica, G ^a   Pinchera, A ^a   Marcocci, C ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Calcimimetics; Calcium sensing receptor; Multiple endocrine neoplasia type 1; Parathyroid hormone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG LABELING; DRUG WITHDRAWAL; ENDOCRINE TUMOR; FEMALE; FOLLOW UP; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PARATHYROIDECTOMY; PRESCRIPTION; PRIMARY HYPERPARATHYROIDISM; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DRUG LABELING; EUROPEAN UNION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MAINTENANCE CHEMOTHERAPY; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NAPHTHALENES; PARATHYROIDECTOMY; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RECEPTORS, CALCIUM-SENSING; SEVERITY OF ILLNESS INDEX;

EID: 84865773237     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7970     Document Type: Article

References (17)

1. AACE/AAES Task Force on Primary Hyperparathyroidism. The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 2005, 11: 49-54.
2. Walker MD, Silverberg SJ. Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Invest 2008, 31: 925-31.
3. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94: 351-65.
4. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008, 93: 3462-70.
5. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009, 94: 366-72.
6. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 1998, 95: 4040-5.
7. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004, 308: 627-35.
8. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88: 5644-9.
9. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90: 135-41.
10. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009, 94: 4860-7.
11. Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 2011, 96: E9-18.
12. Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 2008, 57: 517-21.
13. Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94: 2766-72.
14. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007, 92: 3803-8.
15. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007, 92: 3114-21.
16. Falchetti A, Cilotti A, Vaggelli L, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 2008, 4: 351-7.
17. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol 2010, 2010: 906163.